Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Timothy Ashby and Samer Al Hadidi.

 
Connection Strength
  
 
 
0.643
  
  1. Bauer MA, Farmer P, Su JL, Schootman M, Li C, Van Rhee F, Al Hadidi S, Schinke C, Shaughnessy JD, Zhan F, Ashby C. The invisible divide: the impact of racial and geographic disparities on multiple myeloma outcomes - insights from a single-site study. Haematologica. 2025 Sep 04.
    View in: PubMed
    Score: 0.248
  2. Schinke C, Rasche L, Ashby C, van Hemert R, Thanendrarajan S, Al Hadidi S, Zangari M, Bailey C, Alapat DV, Shaughnessy JD, Zhan F, Barlogie B, van Rhee F, Weinhold N. Prognostic impact of focal lesion location and persistence in multiple myeloma: insights from serial PET/DWI imaging. Blood Adv. 2025 Sep 09; 9(17):4368-4377.
    View in: PubMed
    Score: 0.062
  3. Sun F, Cheng Y, Ma C, Xu H, Bailey C, Mery D, Ashby TC, Alapat D, Li Y, Young KH, Al Hadidi S, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma. Cancer Biomark. 2025 Jun; 42(6):18758592251344936.
    View in: PubMed
    Score: 0.061
  4. Guo W, Strouse C, Mery D, Siegel ER, Munshi MN, Ashby TC, Cheng Y, Sun F, Wanchai V, Zhang Z, Bailey C, Alapat DV, Peng H, Al Hadidi S, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation. Cancers (Basel). 2024 Mar 11; 16(6).
    View in: PubMed
    Score: 0.056
  5. Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H, Gai D, Siegel E, Bailey C, Ashby C, Al Hadidi S, Schinke C, Thanendrarajan S, Ma Y, Yi Q, Orlowski RZ, Zangari M, van Rhee F, Janz S, Bishop G, Tricot G, Shaughnessy JD, Zhan F. Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024 Jan 19; 15(1):615.
    View in: PubMed
    Score: 0.055
  6. Cheng Y, Sun F, Alapat DV, Wanchai V, Mery D, Guo W, Cao H, Zhu Y, Ashby C, Bauer MA, Nookaew I, Siegel ER, Ying J, Chen JR, Gai D, Peng B, Xu H, Bailey C, Al Hadidi S, Schinke C, Thanendrarajan S, Zangari M, Chesi M, Bergsagel PL, van Rhee F, Janz S, Tricot G, Shaughnessy JD, Zhan F. High NEK2 expression in myeloid progenitors suppresses T?cell immunity in multiple myeloma. Cell Rep Med. 2023 10 17; 4(10):101214.
    View in: PubMed
    Score: 0.054
  7. Sun F, Cheng Y, Ying J, Mery D, Al Hadidi S, Wanchai V, Siegel ER, Xu H, Gai D, Ashby TC, Bailey C, Chen JR, Schinke C, Thanendrarajan S, Zangari M, Janz S, Barlogie B, Van Rhee F, Tricot G, Shaughnessy JD, Zhan F. A gene signature can predict risk of MGUS progressing to multiple myeloma. J Hematol Oncol. 2023 06 29; 16(1):70.
    View in: PubMed
    Score: 0.053
  8. Mohan M, Gong Z, Ashby TC, Al Hadidi S, Thanendrarajan S, Schinke C, Alapat D, Shaughnessy JD, Zhan F, van Rhee F, Sawyer JR, Tian E, Zangari M. Concomitant deletion of the short arm (del(1p13.3)) and amplification or gain (1q21) of chromosome 1 by fluorescence in situ hybridization are associated with a poor clinical outcome in multiple myeloma. Cancer. 2023 08 15; 129(16):2491-2498.
    View in: PubMed
    Score: 0.053
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.